Development of Targeted RNA-Seq for Amyotrophic Lateral Sclerosis Diagnosis

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE NĪMES · Oct 9, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to diagnose Amyotrophic Lateral Sclerosis (ALS) by analyzing RNA, which is a molecule that helps carry information from DNA to make proteins in the body. The goal is to improve how we identify genetic causes of ALS, especially for patients who currently do not have a clear genetic diagnosis. By using a technique called RNA sequencing, researchers hope to gather more information about how certain genetic changes might affect the disease. This could lead to better-targeted treatments in the future.

To participate in this trial, you need to have a doctor's prescription for a genetic diagnosis of ALS and be willing to provide informed consent for the study. You should also be a member of a health insurance plan. If you qualify, you can expect to undergo tests that analyze your RNA to help clarify the genetic aspects of ALS. This study is important because it aims to develop a comprehensive method for diagnosing ALS, which could enhance patient care and management.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Have a prescription for a genetic diagnosis of ALS (or familial hypercholesterolemia for the control cohort)
• • Have given their informed consent for the genetic study and the biobank
• • The patient must be a member or beneficiary of a health insurance plan
• Exclusion Criteria:
• • The patient is under safeguard of justice or state guardianship